What is the appropriate tacrolimus dosing adjustment for a pediatric liver transplant patient (history of biliary atresia, Kasai procedure, cadaveric transplant) currently hospitalized after laparoscopic appendectomy for perforated appendix with intra‑abdominal abscess, given a tacrolimus trough level of 14.5 ng/mL?

Reduce Tacrolimus Dose Immediately

The tacrolimus trough level of 14.5 ng/mL is significantly elevated above the recommended target range for a pediatric liver transplant patient beyond the first month post-transplant, and the dose should be reduced to achieve a target trough of 4-8 ng/mL. 1

Current Clinical Context

This patient is well beyond the first post-transplant month (transplanted at 5 months old, now hospitalized for appendiceal complications), placing them in the maintenance immunosuppression phase. The acute infection and intra-abdominal abscess add complexity but do not justify supratherapeutic tacrolimus levels—in fact, excessive immunosuppression during active infection increases morbidity and mortality risk.

Target Trough Levels

According to the 2024 EASL guidelines 1:

• First month post-transplant: 6-10 ng/mL (monotherapy)
• Beyond first month: 4-8 ng/mL (monotherapy)
• With combination therapy (MMF, AZA, or mTORi): 3-5 ng/mL

The current level of 14.5 ng/mL represents the outdated regulatory target of 10-15 ng/mL that has been superseded by evidence showing improved renal function without increased rejection rates at lower levels 1, 2.

Dosing Adjustment Strategy

Immediate Actions:

1. Hold the next 1-2 doses given the significantly elevated trough
2. Reduce the total daily dose by 30-40% when restarting (from 3 mg/day to approximately 1.8-2.1 mg/day divided q12h)
3. Recheck trough level in 48-72 hours after dose adjustment

Pediatric Considerations:

Pediatric patients typically require higher weight-based doses than adults to achieve similar trough concentrations 3, 4, 5. However, this patient's current level suggests either:

• Adequate absorption with current dosing
• Drug-drug interactions (antibiotics for abscess may affect CYP3A metabolism)
• Reduced clearance due to acute illness

Special Considerations for Active Infection

The presence of intra-abdominal abscess mandates minimizing immunosuppression while preventing rejection 6. A recent case report of intra-abdominal mucormycosis in a liver transplant recipient demonstrated successful outcomes with tacrolimus maintained at low trough levels during active infection 6.

Infection-Related Dosing Principles:

• Target the lower end of the therapeutic range (4-6 ng/mL) during active infection
• Monitor closely for rejection with liver enzymes
• Avoid supratherapeutic levels that impair immune response to infection
• Consider adding low-dose corticosteroids if concerned about rejection risk while lowering tacrolimus

Drug Interactions to Evaluate

Check for concurrent medications that inhibit CYP3A4/3A5:

• Azole antifungals (fluconazole, voriconazole)
• Macrolide antibiotics (clarithromycin, erythromycin)
• Calcium channel blockers
• Proton pump inhibitors (modest effect)

Any of these could explain the elevated trough and may require further dose reduction if continued.

Monitoring Plan

1. Trough levels: Check 48-72 hours after each dose adjustment until stable in target range (4-8 ng/mL)
2. Liver function tests: Monitor AST/ALT every 2-3 days to detect subclinical rejection
3. Renal function: Elevated tacrolimus levels cause nephrotoxicity—monitor creatinine closely 1, 2
4. Clinical assessment: Watch for neurotoxicity (tremor, headache, seizures) which is common at levels >8 ng/mL 7

Critical Pitfalls to Avoid

• Do not maintain levels >10 ng/mL based on outdated regulatory guidance—this increases nephrotoxicity without improving rejection rates 2
• Do not delay dose reduction due to infection concerns—excessive immunosuppression worsens infection outcomes
• Do not make small incremental changes—a 30-40% reduction is appropriate for a level this elevated
• Do not forget to assess medication interactions—antibiotics and antifungals commonly used for intra-abdominal infections significantly affect tacrolimus metabolism

Long-Term Maintenance Strategy

Once the acute infection resolves and the patient is stable:

• Target trough: 4-6 ng/mL for monotherapy 1
• Consider adding mycophenolate mofetil to allow even lower tacrolimus levels (3-5 ng/mL range), which optimizes renal function preservation 1
• Pediatric patients often require dose adjustments as they grow, with clearance changing over time 4, 5